All In Biotech

Drug Trial Radar · NCT04366115

Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study Evaluating AVM0703 in Patients With Acute Respiratory Distress Syndrome

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Dec 1, 2031

Study completion Mar 1, 2032

Sponsor

Lead sponsor
AVM Biotechnology IncIndustry
Sponsor type
Industry
First posted
Apr 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 or influenza (A or B). The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single dose of AVM0703 in these ARDS patients.

Conditions

  • ARDS
  • Covid19
  • Influenza, Human

Interventions

  • AVM0703Drug

    Single IV infusion at 10 mg/mL in normal saline over 1 hour to patients.

  • PlaceboDrug

    Single IV infusion in normal saline over 1 hour to patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting ToxicitiesTime frame: 0-12 months
  2. 28 day all-cause mortality will be a primary end point for Phase 1 and 2Time frame: 0-12 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.